Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Guopan Yu, Yishan Chen, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Xin Du, Danian Nie, Ziwen Guo, Zhiqiang Sun, Hongyu Zhang, Dongjun Lin, Xinquan Liang, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Baohong Ping, Qifa Liu

Blood (2024) 144 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2024-201974

Published: 2024

Journal Articles

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Guopan Yu, Zurong Yao, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Ziwen Guo, Zhiqiang Sun, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Qifa Liu

Blood (2024) 144 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2024-206872

Published: 2024

Journal Articles

Quantitative Detection of the Expressions of BCL-2, BCL-Xl and MCL-1 in Bone Marrow Tissues with Immunofluorescence Might Predict the Efficacy of Venetoclax-Based Therapies in Acute Myeloid Leukemia

Xiaqi Nie, Zhao Yin, Zurong Yao, Dandan Chen, Qifa Liu, Guopan Yu

Blood (2024) 144 (Supplement 1): 6109.

https://doi.org/10.1182/blood-2024-208001

Published: 2024

Journal Articles

Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study

Sijian Yu, Qifa Liu, Yu Zhang, Guopan Yu, Yu Wang, Ruoyang Shao, Qiong Liu

Blood (2023) 142 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2023-182638

Published: 2023

Journal Articles

Comparison of Two Venetoclax-Based Regimens As Salvage Therapies Bridged to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Yiling Ye, Yanqiu Chen, Guopan Yu, Guangyang Weng, Qifa Liu, Hua Jin

Blood (2023) 142 (Supplement 1): 7104.

https://doi.org/10.1182/blood-2023-181616

Published: 2023

Journal Articles

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Guopan Yu, Zhao Yin, Zurong Yao, Xiaqi Nie, Hua Jin, Yu Zhang, Dan Xu, Xuejie Jiang, Baohong Ping

Blood (2023) 142 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2023-182668

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Guopan Yu, Zhao Yin, Jixian Huang, Huiqing He, Xuejie Jiang, Hongsheng Zhou, Pengcheng Huang, Yu Zhang

Blood (2023) 142 (Supplement 1): 5862.

https://doi.org/10.1182/blood-2023-182621

Published: 2023

Journal Articles

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Yu Zhang, Xuejie Jiang, Xiaqi Nie, Zurong Yao, Dan Xu, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2023-184772

Published: 2023

Journal Articles

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Guopan Yu, Yu Zhang, Hua Jin, Zhao Yin, Guangyang Weng, Sijian Yu, Na Xu, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo, Weihua Zhao, Min Dai, Xuejie Jiang, Li Xuan, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2023-182847

Published: 2023

Journal Articles

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Qixin Sun, Zhengqian Huang, Yu Zhang, Guopan Yu

Blood (2022) 140 (Supplement 1): 9097.

https://doi.org/10.1182/blood-2022-159589

Published: 2022

Journal Articles

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Guopan Yu, Zhao Yin, Dan Xu, Xuejie Jiang, Jieyu Ye, Yu Zhang

Blood (2022) 140 (Supplement 1): 11740.

https://doi.org/10.1182/blood-2022-169333

Published: 2022

Journal Articles

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Pengcheng Shi, Xi Jia, Naying Liao, Yin Changxin, Huan Li, Xuejie Jiang, Guopan Yu, Jieyu Ye, Hong Qu, Yu Zhan, Chunju Wen, Yu Zhang, Qifa Liu

Blood (2022) 140 (Supplement 1): 2005–2006.

https://doi.org/10.1182/blood-2022-156348

Published: 2022

Journal Articles

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Hua Jin, Sijian Yu, Yuhua Li, Danian Nie, Ziwen Guo, Zhiqiang Sun, Qingxiang Meng, Weihua Zhao, Dongjun Lin, Na Xu, Yu Zhang

Blood (2022) 140 (Supplement 1): 11796.

https://doi.org/10.1182/blood-2022-168004

Published: 2022

Journal Articles

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Guangyang Weng, Yu Zhang, Guopan Yu, Na Xu, Zhiqiang Sun, Dongjun Lin, Xinquan Liang, Lan Deng, Jie Xiao, Hongyu Zhang, Ziwen Guo, Hua Jin, Xin Du, Qifa Liu

Blood (2022) 140 (Supplement 1): 2025–2026.

https://doi.org/10.1182/blood-2022-158762

Published: 2022

Journal Articles

Cidofovir, a Choice for Salvage Treatment of CMV Infection in the Patients with Haploidentical Hematopoitic Stem Cell Transplantation

Zhao Yin, Na Xu, Ling Jiang, Pengcheng Shi, Zhiping Fan, MD, Fen Huang, Qifa Liu, MD, Jing Sun, Guopan Yu

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-138685

Published: 2020

Journal Articles

Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia

Guopan Yu, Na Xu, Fen Huang, Zhiping Fan, MD, Hui Liu, Pengcheng Shi, Hongsheng Zhou, MD PhD, Zhixiang Wang, Yu Zhang, Qifa Liu, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138676

Published: 2020

Journal Articles

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hongying Zhang, MD, PhD, Charlie Ly, BS, Bin Yuan, Vivian Ruvolo, MS, Sujan Piya, PhD, Seemana Bhattacharya, PhD, Qi Zhang, PhD, Gautam Borthakur, MD, Venkata Lokesh Battula, PhD, Marina Y. Konopleva, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2018-99-116643

Published: 2018

Journal Articles

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Guopan Yu, Jiaheng Zhou, Jinchan Zhou, Jiale Qiu, Zhao Yin, Changxin Yin, Dan Xu, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2018-99-116558

Published: 2018

Journal Articles

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Xuejie Jiang, MD, Changxin Yin, Junya Sun, Jiaying Cheng, Qiang Wang, Guopan Yu, Ling Jiang, Dan Xu, Xiaoli Liu, Ru Feng, MD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2018-99-111063

Published: 2018

Journal Articles

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Guopan Yu, Changxin Yin, Fuqun Wu, Ling Jiang, Zhongxin Zheng, Dan Xu, Jiaheng Zhou, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5249.

https://doi.org/10.1182/blood-2018-99-113494

Published: 2018

NARROW

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Quantitative Detection of the Expressions of BCL-2, BCL-Xl and MCL-1 in Bone Marrow Tissues with Immunofluorescence Might Predict the Efficacy of Venetoclax-Based Therapies in Acute Myeloid Leukemia

Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study

Comparison of Two Venetoclax-Based Regimens As Salvage Therapies Bridged to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Cidofovir, a Choice for Salvage Treatment of CMV Infection in the Patients with Haploidentical Hematopoitic Stem Cell Transplantation

Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only